

Serum Institute of India invests in needle-free injection system technology

17 May 2024 | News

With this investment, SII will acquire 20% stake in IntegriMedical



Serum Institute of India (SII) has announced a strategic investment in Pune-based startup IntegriMedical, acquiring a 20% stake in the company, to advance Needle-Free Injection System technology.

The partnership between SII and IntegriMedical aligns with SII's vision of 'Health for All' and IntegriMedical's mission to 'Transform Healthcare Globally' by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion.

IntegriMedical has developed a US patented Needle-Free Injection System (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs. The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a pleasant and stress-free experience.

Commenting on the strategic investment, Adar Poonawalla, CEO, Serum Institute of India, shared, "IntegriMedical's Needle-Free Injection Systems (N-FIS) represent a significant advancement in drug delivery and we envision a needle-free solution to deliver vaccines."

IntegriMedical's Needle-Free Injections System also known as N-FIS has received regulatory approvals from CDSCO, CE, MDSAP and is ISO 13485 certified.

N-FIS will be available in the Indian private market, offering patients and healthcare providers an alternative to traditional needle-based injections. The technology's advantages include the elimination of needle-phobia, alleviation of pain during administration, convenience of use, and prevention of needle-stick injuries and cross-contamination.